Abstract: Due to systemic and local factors, patients with rheumatic immune system diseases often suffer from osteoporosis. However, because of different pathogenesis, the bone metabolism characteristics and anti-osteoporosis treatments of each disease are different. Besides, there are many drugs for rheumatic immune system diseases, and the effects of drugs on bone metabolism need to be clarified. Therefore, this review summarizes the epidemiology, related risk factors and possible mechanisms, changes in bone damage, and the current recommendations and applications of screening, diagnosis and treatment, in order to provide reference for the diagnosis, treatment and management of secondary osteoporosis related to rheumatic immune system diseases.